Thrashed by a 'surprise' rival, Sanofi writes off $2B on soured hemophilia deal

Sanofi wrote off $2 billion after watching the market for its hemophilia drug Eloctate shrivel in the face of Roche’s new star, Hemlibra. Sales dropped 11% and appear pointed firmly south.